What Happened
Denmark's patient compensation authority has now paid 31 people who developed non-arteritic anterior ischaemic optic neuropathy, or NAION, after taking Novo Nordisk's semaglutide products, Ozempic and Wegovy. The awards total about 15 million Danish kroner, about $2.3 million.
The body has reviewed 94 claims: 29 rejected, 34 still under review. A year ago it had ruled on only five claims and approved four, with those first awards totaling 800,000 kroner and open to increase if claimants later documented lost earnings.
The decisions come from Danish Patient Compensation, an independent body financed by the state and insurers. Claimants do not sue and need not show wrongdoing, but compensation is not automatic: the authority cannot pay where NAION developed long after a patient stopped the drug.
Who Is Affected
- The 94 Danish claimants, of whom 31 have been paid, 29 rejected and 34 are still waiting
- U.S. patients, where no equivalent no-fault scheme exists and injury claims proceed as unproven lawsuits
- Buyers of unapproved semaglutide vials, who receive no regulator-mandated label warning at all
Timeline
- November 2025 — The authority announces its first four NAION awards, 800,000 kroner in total, after reviewing five claims
- 2025 — The European Medicines Agency classifies NAION as a very rare side effect of semaglutide, up to 1 in 10,000 users, and Novo updates European leaflets; Denmark requested that review after two Danish studies linked Ozempic to higher risk
- November 9, 2026 — The U.S. Food and Drug Administration requires a NAION warning across the entire GLP-1 class
- November 19, 2026 — The 31-patient Danish total is reported, ten days after the FDA action
- Ongoing — 34 Danish claims still undecided
What This Means for Researchers
Compensation is not causation. A no-fault award means one patient's injury met Denmark's statutory criteria; it is not a finding that semaglutide causes NAION across a population, and not a judgment against Novo Nordisk, which maintains it sees no causal link and a favourable benefit-risk profile.
The absolute numbers are small in both directions. The FDA's pooled review of more than 125 trials found roughly six NAION cases per 100,000 patients treated with a GLP-1 for at least a year, against fewer than four per 100,000 on placebo or other glucose-lowering medicines. NAION already occurs in two to ten of every 100,000 adults over 50 who take no such drug, and the highest-risk groups overlap heavily with GLP-1 users.
For anyone studying grey-market semaglutide, the figures carry a separate caveat: unapproved vials ship with no NAION warning and no batch-linked pharmacovigilance, so an absence of reports reflects an absence of surveillance, not an absence of risk.
How to Verify Your Peptides
For laboratory material, identity and purity should be documented batch by batch: mass spectrometry for identity, HPLC for purity, and a certificate of analysis naming the specific lot. Our guides on how testing works and HPLC versus LC-MS explain what a credible report contains.
Safe Alternatives
Semaglutide is a prescription medicine, and whether to start, continue or stop it belongs with a clinician who can weigh the eye signal against cardiovascular and glycaemic benefit. Our compound pages document trial data and regulatory status for semaglutide and tirzepatide; the vendor directory lists suppliers publishing third-party testing.
Sources
- Danish Patient Compensation (Patienterstatningen), NAION claim decisions, November 2025 and November 2026
- European Medicines Agency safety review of semaglutide and NAION, 2025
- U.S. Food and Drug Administration, class-wide GLP-1 labelling action, November 9, 2026
- Regulatory announcements and industry reports on Danish claim totals, November 2026